Shifting the lines against central nervous system disorders

« Neurological disorders: a major social challenge and a market in crucial need of therapeutic innovation »

> Management

Franck MOUTHON, Chairman and CEO

Franck MOUTHON, Chairman and CEO

Franck Mouthon holds a degree in life sciences from the École Normale Supérieure (ENS-Ulm) and a master's degree in biology from the ENS and Paris VI, VII and XI interuniversity program. He is an alumni of the medical virology program at the Institut Pasteur and participated in the HEC Challenge + entrepreneur program. He has 15 years of experience in team and project management. He joined the Life Sciences Department of the French Alternative Energies and Atomic Energy Commission (CEA) in 1995 where he worked on neurodegenerative diseases at the Institute of Emerging Diseases and Innovative Therapies (IMETI). He has published various papers and filed several patents related to the modulation of drugs targeting neurons. In March 2013, he co-founded Theranexus with Mathieu Charvériat, having obtained the exclusive worldwide rights to the technology they identified at the CEA. He is Chairman of the Board of Directors and Chief Executive Officer. He is also an administrator of France Biotech.

Mathieu CHARVERIAT, Chief Scientific Officer and Deputy CEO

Mathieu CHARVERIAT, Chief Scientific Officer and Deputy CEO

Mathieu Charvériat holds degrees from the École Polytechnique and Mines ParisTech, as well as a PhD in neurosciences and cell biology from the Université Pierre & Marie Curie. He also participated in the HEC Challenge + entrepreneur program with Franck Mouthon. He joined the neurosciences research laboratory of the French Alternative Energies and Atomic Energy Commission (CEA) in 2009, working with Franck Mouthon on prion diseases and non-neuronal cells, where together they published various papers and filed several patents related to the modulation of drugs targeting neurons. In March 2013, he co-founded Theranexus with Franck Mouthon. As part of his duties as Chief Scientific Officer, Mathieu Charvériat is responsible for the company's research teams and scientific partnerships. He is also Deputy CEO and a director.

Julien VEYS, Chief Business Development Officer

Julien VEYS, Chief Business Development Officer

Julien Veys holds a master’s degree in biochemistry and in information and intelligence management from Aix-Marseille University. He has 15 years of experience in the health industry. After working for a contract research organization (CRO), he joined Trophos (a biotech company specialized in neurodegenerative diseases) in 2005, where he held various successive positions, including Chief Business Development Officer, up until the sale of Trophos to Roche Laboratories for €470 million in 2015. He became Chief Business Development Officer of Theranexus in early 2016.

Werner REIN, Chief Medical Officer

Werner REIN, Chief Medical Officer

Werner Rein holds a PhD in neurology and psychiatry, and has taught at the University of Tübingen in Germany and worked as a consultant at the Hôpital Cochin. He has held various clinical management positions, including that of Vice President of the Clinical Investigations Psychiatry Department at Sanofi. Since 2010, he has worked as a consultant to help develop drugs that treat central nervous system disorders. He is also a member of the French National Research Agency's University Research Hospital panel and serves as an expert consultant for BPI (as part of the Worldwide Innovation Challenge). He became Chief Medical Officer of Theranexus in 2017.

Thierry LAMBERT, Chief Financial Officer

Thierry LAMBERT, Chief Financial Officer

Thierry Lambert holds a degree in business administration from Birmingham University and an MBA from INSEAD. He is also a qualified chartered accountant and ICAEW-certified statutory auditor (Institute of Chartered Accountants in England and Wales). He worked for five years at PwC and four years in syndicated and corporate finance before being successively appointed as Chief Financial Officer for listed companies Naturex (specialized in ingredients for the health and food industries) and Safe Orthopaedics (specialized in spinal implants). He became Chief Financial Officer of Theranexus in 2017.